Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

Inclusion Criteria: Patients eligible for inclusion in this trial must meet all of the following criteria: 1. Patients \>18 years (no upper age limit); 2. AML (WHO) or intermediate or higher risk MDS/ Chronic Myelomonocytic Leukemia (CMML) (IPSS-R \>3.0); 3. No standard treatment available (comorbidities, higher age, refractoriness to standard or salvage chemotherapy and allografting, azanucleosides failure\*); 4. Patients with \< 30.000 leukocytes/µl; 5. Eastern Cooperative Oncology Group (ECOG) 0,1,2; 6. Written informed consent obtained according to international guidelines and local laws; 7. Ability to understand the nature of the trial and the trial related procedures and to comply with them. * Azanucleosides failure is defined as 1) no response after at least three (AML) or six (MDS) cycles of azacitidine or decitabine, 2) disease progression under treatment or 3) grade 3-4 non-hematologic toxicity. Exclusion Criteria: Patients eligible for this trial must not meet any of the following criteria: 1. Acute promyelocytic leukemia (APL, French-American-British classification system (FAB) M3); 2. Eligibility for standard induction or consolidation chemotherapy, immediate allografting, or a hypomethylating agent; 3. AML with central nervous system (CNS) involvement; 4. AraC treatment within one month prior to registration; 5. Prior exposure to histone deacetylase inhibitors, including sodium valproate within one month prior to registration; 6. Stem cell transplant patient with graft-versus-host disease (GvHD) or under systemic immunosuppression; 7. Previous gastrointestinal surgery that might interfere with drug absorption; 8. Pheochromocytoma; 9. Carcinoid tumor; 10. Confirmed or suspected cerebrovascular disease; 11. Vascular malformations including aneurysm; 12. Severe renal insufficiency; 13. Severe or poorly controlled hypertension; 14. Severe cardiovascular disease; 15. Hepatic insufficiency/liver disease; 16. Porphyria; 17. Diabetes insipidus; 18. History or presence of malignant hyperthermia; 19. Known psychiatric disorders; 20. Known allergy against soy beans or peanuts; 21. Known hypersensitivity to or intolerance of one of the trial drugs or its constituents (e.g. lactose, corn starch, indigocarmine (TCP), corn starch (AraC), other retinoids (ATRA)); 22. Simultaneous intake of the prohibited medication, incl. linezolid, that is likely to cause interactions (see detailed list study protocol); 23. Patients who refuse to follow study-specific dietary guidelines; 24. Known or persistent abuse of medication, drugs or alcohol; 25. Current or planned pregnancy, nursing period; 26. Failure to use safe methods of contraception; 27. Simultaneous participation in other interventional trials which could interfere with this trial and/or participation before the end of a required restriction period; 28. Participation in a clinical trial within the last 30 days before the start of this trial 29. Persons who are in a relationship of dependence/employment with the sponsor or the investigator;